GHRP-6 monograph

GHRP-6

Overview

GHRP-6 is a synthetic growth hormone secretagogue peptide studied mainly in preclinical and small human experimental settings. It is best thought of as a short-acting ghrelin-mimetic that can stimulate growth hormone release and, commonly, appetite. It is not an FDA-approved medicine, and bodybuilding use is off-label/black-market with limited human dosing and safety data.

Pharmacokinetics & Mechanism

• Class: Growth hormone secretagogue peptide; ghrelin-mimetic peptide
• Mechanism of action: GHRP-6 stimulates pulsatile growth hormone release by activating the growth hormone secretagogue pathway and mimicking ghrelin-like signaling. In practical terms, it acts at the ghrelin/GHSR axis to increase hypothalamic-pituitary GH secretion; downstream effects include increased IGF-1 over time if exposure is sufficient. Human clinical development has been limited, so exact dose-response and long-term endocrine consequences are not well established.
• Target(s): Primary target: growth hormone secretagogue receptor 1a (GHSR-1a, ghrelin receptor) / ghrelin axis. Downstream pathway: hypothalamic GHRH/GH pulse amplification with pituitary GH release; appetite pathways in the CNS are also engaged. Exact binding affinity and full human pathway mapping are not well established for coaching use.
• Route(s) of administration: Subcutaneous injection is the practical route used in peptide protocols; other parenteral routes are not standard for coaching use. Oral bioavailability is not established and would be expected to be poor for a peptide. Not an approved product with a validated labeled route.
• Onset: Rapid, short-acting response after injection is expected; community use commonly times it pre-meal or before bed, but precise human onset data are not well established. GH pulse effects are typically described within tens of minutes in experimental settings, not hours.
• Half-life: Short. GHRP-6 is generally described as having a plasma half-life on the order of minutes, with commonly cited estimates around about 15 minutes; exact human pharmacokinetic data are limited and should be treated cautiously. Any extended-duration effect would be from repeated dosing, not a long intrinsic half-life. DAC/long-acting variants are not established for GHRP-6 itself.
• Metabolism / clearance: Likely cleared rapidly by peptidases and general peptide catabolism after parenteral administration; renal/hepatic contribution is not well established in humans. No robust human mass-balance or labeled clearance data were found. Because the compound is a peptide, storage/handling and peptide degradation are relevant practical issues.